Champions Oncology (NASDAQ:CSBR – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its competitors? We will compare Champions Oncology to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Risk and Volatility
Champions Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Champions Oncology’s competitors have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.
Earnings and Valuation
This table compares Champions Oncology and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | -$1.17 million | -61.94 |
| Champions Oncology Competitors | $2.26 billion | $55.88 billion | -13.93 |
Champions Oncology’s competitors have higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 54.4% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Champions Oncology and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| Champions Oncology Competitors | -540.59% | -166.46% | -13.58% |
Analyst Recommendations
This is a summary of current recommendations for Champions Oncology and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Champions Oncology Competitors | 947 | 3162 | 5475 | 177 | 2.50 |
As a group, “Life Sciences Tools & Services” companies have a potential downside of 4.19%. Given Champions Oncology’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Champions Oncology has less favorable growth aspects than its competitors.
Summary
Champions Oncology competitors beat Champions Oncology on 9 of the 13 factors compared.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
